TCGA-OR-A5JJ-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.476
- MYC_TARGETS_V2+0.444
- G2M_CHECKPOINT+0.390
- MYC_TARGETS_V1+0.364
- SPERMATOGENESIS+0.232
- INTERFERON_ALPHA_RESPONSE+0.195
- PANCREAS_BETA_CELLS+0.151
- ESTROGEN_RESPONSE_LATE+0.140
- DNA_REPAIR+0.119
- KRAS_SIGNALING_DN+0.103
Top 10 suppressed
- TGF_BETA_SIGNALING-0.371
- PROTEIN_SECRETION-0.352
- UV_RESPONSE_DN-0.350
- PI3K_AKT_MTOR_SIGNALING-0.321
- HEME_METABOLISM-0.320
- TNFA_SIGNALING_VIA_NFKB-0.319
- IL6_JAK_STAT3_SIGNALING-0.294
- ANGIOGENESIS-0.287
- COMPLEMENT-0.265
- INFLAMMATORY_RESPONSE-0.252
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518133 | — | E | 0.821 |
| 2 | BS_YEW22W35 | high-grade glioma | — | 0.816 |
| 3 | BS_2Z1MKS84 | medulloblastoma | — | 0.816 |
| 4 | TCGA-22-5481-01A-31R-1949-07 | — | cohortMD1 | 0.814 |
| 5 | TCGA-HN-A2NL-01A-11R-A18M-07 | — | E | 0.811 |
| 6 | MNG80 | — | — | 0.810 |
| 7 | C3N-04162 | — | cohortSQ2 | 0.805 |
| 8 | R175 | — | — | 0.804 |
| 9 | MBCproject_0227_T1_RNA | — | C | 0.802 |
| 10 | SRR8518130 | — | E | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.476 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.444 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.364 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.232 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.195 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.151 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.119 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.103 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.079 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.065 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.044 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.002 | Inavolisib | — uncovered |